Top-Rated StocksTop-RatedNASDAQ:AXSM Axsome Therapeutics (AXSM) Stock Price, News & Analysis $86.53 +0.55 (+0.64%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$85.05▼$86.9350-Day Range$71.07▼$86.0552-Week Range$55.02▼$98.40Volume262,192 shsAverage Volume706,856 shsMarket Capitalization$4.11 billionP/E RatioN/ADividend YieldN/APrice Target$123.85 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Axsome Therapeutics alerts: Email Address Axsome Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.93 Rating ScoreUpside/Downside43.1% Upside$123.85 Price TargetShort InterestBearish17.43% of Shares Sold ShortDividend StrengthN/ASustainability-1.03Upright™ Environmental ScoreNews Sentiment0.64Based on 26 Articles This WeekInsider TradingSelling Shares$982,569 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.66) to ($0.18) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.69 out of 5 starsMedical Sector67th out of 936 stocksPharmaceutical Preparations Industry22nd out of 436 stocks 4.5 Analyst's Opinion Consensus RatingAxsome Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 13 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAxsome Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Axsome Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted17.43% of the outstanding shares of Axsome Therapeutics have been sold short.Short Interest Ratio / Days to CoverAxsome Therapeutics has a short interest ratio ("days to cover") of 12, which indicates bearish sentiment.Change versus previous monthShort interest in Axsome Therapeutics has recently decreased by 3.50%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAxsome Therapeutics does not currently pay a dividend.Dividend GrowthAxsome Therapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAxsome Therapeutics has received a 69.39% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is driven by its "Clinical research services for mental health" product. See details.Environmental SustainabilityThe Environmental Impact score for Axsome Therapeutics is -1.03. Previous Next 2.6 News and Social Media Coverage News SentimentAxsome Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 26 news articles for Axsome Therapeutics this week, compared to 6 articles on an average week.Search InterestOnly 8 people have searched for AXSM on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat Follows8 people have added Axsome Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Axsome Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $982,569.00 in company stock.Percentage Held by Insiders22.40% of the stock of Axsome Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions81.49% of the stock of Axsome Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Axsome Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Axsome Therapeutics are expected to grow in the coming year, from ($4.66) to ($0.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Axsome Therapeutics is -13.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Axsome Therapeutics is -13.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxsome Therapeutics has a P/B Ratio of 21.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Axsome Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Axsome Therapeutics Stock (NASDAQ:AXSM)Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Read More AXSM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AXSM Stock News HeadlinesJuly 24 at 4:39 AM | ca.finance.yahoo.comAXSM Jan 2026 30.000 putJuly 24 at 4:39 AM | msn.comNeedham Initiates Coverage of Axsome Therapeutics (AXSM) with Buy RecommendationJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 23 at 2:57 PM | investorplace.com7 Biotech Stocks to Keep on Your Clinical RadarJuly 23 at 5:23 AM | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Coverage Initiated by Analysts at Needham & Company LLCJuly 23 at 4:31 AM | seekingalpha.comAxsome Therapeutics: Lots Of Moving PartsJuly 23 at 4:31 AM | msn.comNeedham starts Axsome at buy, cites revenue growth potentialJuly 22, 2024 | benzinga.comAxsome Therapeutics' CNS Portfolio Poised for Major Growth - Analyst Predicts Strong FutureJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 22, 2024 | markets.businessinsider.comRBC Capital Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)July 22, 2024 | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Rating Reiterated by Royal Bank of CanadaJuly 22, 2024 | markets.businessinsider.comBuy Rating Justified: Strong Performance and Promising Outlook for Axsome’s AuvelityJuly 20, 2024 | americanbankingnews.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Expected to Post Q2 2024 Earnings of ($1.33) Per ShareJuly 19, 2024 | markets.businessinsider.comAxsome Therapeutics: Stable Auvelity Growth and Coverage Amid New GPO ContractJuly 19, 2024 | markets.businessinsider.comWall Street Analysts Predict a 49.36% Upside in Axsome: Here's What You Should KnowJuly 19, 2024 | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) PT Lowered to $95.00 at Bank of AmericaJuly 15, 2024 | fool.comBull Market and Beyond: 2 Stocks Just Waiting to SoarJuly 5, 2024 | investorplace.comThe 3 Best Biotech Stocks to Buy in July 2024See More Headlines Receive AXSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today7/26/2024Next Earnings (Confirmed)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AXSM CUSIPN/A CIK1579428 Webaxsome.com Phone(212) 332-3241Fax212-320-0245Employees545Year FoundedN/APrice Target and Rating Average Stock Price Target$123.85 High Stock Price Target$190.00 Low Stock Price Target$95.00 Potential Upside/Downside+43.1%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($6.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-239,240,000.00 Net Margins-118.07% Pretax Margin-118.71% Return on Equity-87.17% Return on Assets-32.81% Debt Debt-to-Equity Ratio1.25 Current Ratio3.20 Quick Ratio3.09 Sales & Book Value Annual Sales$270.60 million Price / Sales15.19 Cash FlowN/A Price / Cash FlowN/A Book Value$4.04 per share Price / Book21.42Miscellaneous Outstanding Shares47,500,000Free Float36,857,000Market Cap$4.11 billion OptionableOptionable Beta1.26 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Herriot Tabuteau M.D. (Age 56)Founder, Chairman, CEO & President Comp: $1.32MMr. Hunter Murdock Esq. (Age 44)General Counsel & Secretary Comp: $735.39kKey CompetitorsGlobal Blood TherapeuticsNASDAQ:GBTRa PharmaceuticalsNASDAQ:RARXAimmune TherapeuticsNASDAQ:AIMTHarmony BiosciencesNASDAQ:HRMYTaro Pharmaceutical IndustriesNYSE:TAROView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 11,793 shares on 7/26/2024Ownership: 0.349%AlphaCentric Advisors LLCSold 17,500 shares on 7/26/2024Ownership: 0.032%Hennion & Walsh Asset Management Inc.Sold 4,798 shares on 7/20/2024Ownership: 0.136%China Universal Asset Management Co. Ltd.Sold 3,523 shares on 7/20/2024Ownership: 0.012%Assenagon Asset Management S.A.Bought 33,969 shares on 7/18/2024Ownership: 0.072%View All Insider TransactionsView All Institutional Transactions AXSM Stock Analysis - Frequently Asked Questions How have AXSM shares performed this year? Axsome Therapeutics' stock was trading at $79.59 at the start of the year. Since then, AXSM stock has increased by 8.7% and is now trading at $86.53. View the best growth stocks for 2024 here. How were Axsome Therapeutics' earnings last quarter? Axsome Therapeutics, Inc. (NASDAQ:AXSM) released its quarterly earnings results on Monday, May, 6th. The company reported ($1.09) earnings per share for the quarter, beating the consensus estimate of ($1.20) by $0.11. The business earned $75 million during the quarter, compared to analysts' expectations of $69.91 million. Axsome Therapeutics had a negative net margin of 118.07% and a negative trailing twelve-month return on equity of 87.17%. When did Axsome Therapeutics IPO? Axsome Therapeutics (AXSM) raised $52 million in an initial public offering on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager. Who are Axsome Therapeutics' major shareholders? Axsome Therapeutics' top institutional investors include Bank of New York Mellon Corp (0.35%), Hennion & Walsh Asset Management Inc. (0.14%), Assenagon Asset Management S.A. (0.07%) and CWM LLC (0.05%). Insiders that own company stock include Roger Jeffs, Mark Coleman, Mark L Jacobson, Nick Pizzie and Mark E Saad. View institutional ownership trends. How do I buy shares of Axsome Therapeutics? Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Axsome Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU) and Pfizer (PFE). This page (NASDAQ:AXSM) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Axsome Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
